Skip to content

Clinical trial of noninvasive ventilator XVENT XVM20 FrontlinerTM

Assessing the efficacy of X-VENT ventilation: a performance comparison with continuous positive airway pressure and bilevel positive airway pressure modes

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN68812324
Enrollment
20
Registered
2025-07-13
Start date
2020-07-01
Completion date
Unknown
Last updated
2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Desaturation (SpO2 <95%) not requiring invasive ventilation Respiratory

Interventions

Initially, the XVENT™ XMV20 Frontliner was connected to an oxygen source with a flow rate of 15 L/min. A nasal mask was then applied to the patient, ensuring a tight yet comfortable fit without air le

Sponsors

Xirka Dama Persada Ltd
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Decreased oxygen saturation (SpO2 <95%) 2. Respiratory rate 28 - 30 times per minute

Exclusion criteria

Exclusion criteria: 1. Moderate to severe impaired consciousness (Glasgow Coma Scale score 120 beats per minute) 3. Respiratory failure requiring invasive ventilation and admission to the Intensive Care Unit (ICU)

Design outcomes

Primary

MeasureTime frame
1. Peripheral oxygen saturation (SpO2) measured using a finger pulse oximeter at baseline, every 15 minutes during the first 3 hours and every 2 hours for the subsequent 51 hours, resulting in a total observation period of 54 hours 2. Respiratory rate measured using XVENT XVM20 FrontlinerTM flow sensor, displayed on the device’s monitor at baseline, every 15 minutes during the first 3 hours and every 2 hours for the subsequent 51 hours, resulting in a total observation period of 54 hours 3. Blood pressure measured using an external pressure sensor at baseline, every 15 minutes during the first 3 hours and every 2 hours for the subsequent 51 hours, resulting in a total observation period of 54 hours 4. Heartbeat rate measured using external pulse sensor at baseline, every 15 minutes during the first 3 hours and every 2 hours for the subsequent 51 hours, resulting in a total observation period of 54 hours 5. Patient comfort assessed using a 5-point Agitation Numeric Scale, where a score of 1 indicated very uncomfortable and agitated, and a score of 5 indicated very comfortable and relaxed at baseline, every 15 minutes during the first 3 hours and every 2 hours for the subsequent 51 hours, resulting in a total observation period of 54 hours 6. Adverse events recorded during the experiment and 1 day after the experiment

Secondary

MeasureTime frame
1. Electrical stability, assessed by observing for any unexpected power loss or shutdown during device operation at baseline, every 15 minutes during the first 3 hours and every 2 hours for the subsequent 51 hours, resulting in a total observation period of 54 hours 2. Noise stability, evaluated based on whether the device generates excessive or abnormal noise during use at baseline, every 15 minutes during the first 3 hours and every 2 hours for the subsequent 51 hours, resulting in a total observation period of 54 hours 3. Temperature stability, determined by monitoring for any sudden increase in device temperature due to inadequate heat dissipation at baseline, every 15 minutes during the first 3 hours and every 2 hours for the subsequent 51 hours, resulting in a total observation period of 54 hours 4. Pressure delivery stability, assessed by verifying whether the device consistently delivers the desired CPAP/EPAP and IPAP pressures over time at baseline, every 15 minutes during the first 3 hours and every 2 hours for the subsequent 51 hours, resulting in a total observation period of 54 hours 5. Inspiratory and expiratory time stability, evaluated by checking whether the device accurately delivers IPAP and EPAP according to the preset inspiratory and expiratory durations at baseline, every 15 minutes during the first 3 hours and every 2 hours for the subsequent 51 hours, resulting in a total observation period of 54 hours

Countries

Indonesia

Contacts

Public ContactJenifer Kiem Aviani
jenifer_kiem@yahoo.co.id+62 (0)857 9449 5885

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026